actuatetherapeutics.com (ACTU) - Revenue and Sales Volume

Symbol and logo of brand actuatetherapeutics.com (ACTU)

Actuate Therapeutics, Inc. (ACTU) is building a powerful R&D foundation by focusing on the retention of top researchers and the strategic hiring of clinical experts. The company's overall execution dynamics clearly demonstrate the results of this strategy, where the 0.00 metric determines this level. The development of kinase inhibitors to combat glioblastoma in the B2B segment currently outweighs the lack of operating profit and total dependence on external financing.

Company Sales: Actuate Therapeutics Inc. (ACTU) for 08/14/2024 - 11/18/2026

Comprehensive metric breakdowns and analytics for Actuate Therapeutics Inc. (ACTU)

General company analysis:Actuate Therapeutics, Inc., ACTU
Core merchandise of Actuate Therapeutics

Actuate Therapeutics, Inc. (ACTU) sales reflect total gross revenue from product realization, serving as a fundamental indicator of market demand and cash flow. Investors evaluate revenue dynamics to determine business scaling rates by analyzing the company's sales volatility. This metric allows for the identification of asset stagnation or overheating. For Actuate Therapeutics, Inc. (ACTU), growth in this indicator correlates directly with the commercial success of the GSK-3 inhibitor. The therapeutic value of the drug will determine the company's future financial stability.

Key competitors

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue